Perspectives on the COVID-19 pandemic impact on cardio-oncology: results from the COVID-19 International Collaborative Network survey
Kerry Skurka(Franciscan Health Indianapolis), Lavanya Kondapalli(Moffitt Cancer Center), Sebastian Szmit, Arjun K. Ghosh(Royal London Hospital), Luis E. Raez(Florida International University), Lauren A. Baldassarre(Yale University), Monika Leja(University of Michigan), Vlad G. Zaha(Southwestern Medical Center), Jorge A. Lax(University of Minnesota), Zeina Nahleh(Cleveland Clinic Florida), Sherry‐Ann Brown(Medical College of Wisconsin), Anne Blaes(University of Minnesota), Husam Abdel‐Qadir(University Health Network), Andrés J. Daniele(Universidad de Buenos Aires), J. Raikhelkar(Columbia University Irving Medical Center), Susan Dent(Government of the United States of America), Leah Elson(Yale University), Brenton Bauer(Torrance Memorial Medical Center), Eric H. Yang(University of California, Los Angeles), Jeanne M. DeCara(University of Chicago), Anita Arnold(St Bartholomew's Hospital), Roohi Ismail-Khan(Argerich Hospital), Daniel Sierra Lara(Franciscan Health Indianapolis), Franck Thuny, Diego Sadler(University of Chicago), Nausheen Akhter, Joerg Herrmann(Mayo Clinic), Rupal O’Quinn(Aix-Marseille Université), Tochukwu Okwuosa, Carolina Maria Pinto Domingues Carv Silva(Universidade de São Paulo), Rohit Moudgil(Cleveland Clinic), Vijay Rao(Franciscan Health Indianapolis)
Cited by 28
Related Papers
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)
|European Heart Journal|2022|2.7k
Baseline Cardiovascular Risk Assessment in Cancer Patients Scheduled to Receive Cardiotoxic Cancer Therapies: A Position Statement and New Risk Assessment Tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in Collaboration with the International Cardio-Oncology Society
|European Journal of Heart Failure|2020|767
Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC
|Journal of Thoracic Oncology|2018|661
Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer
|Journal of Thoracic Oncology|2021|642
Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement
|European Heart Journal|2021|589